X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Precigen regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform. Precigen will utilize the UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T targets, CD19 and BCMA.
Lead Product(s): Autologous CAR-T Cell-based Therapy,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PRGN-3007
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Precigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Details:
Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2022
Details:
Patients with solid tumors represents a large unmet medical need, and the results from the first patient are quite promising that our TCR-T cell therapy may offer them hope.
Lead Product(s): TCR-T Cell Therapy,Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company’s TCR-T Cell Therapy.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
The TCR-T Cell Therapy is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2022
Details:
To define the incidence of dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of T-Cell Receptor T cells (herein referred to as TCR-T cell drug product administered without IL-2 (Arm A) or with IL-2 (Arm B).
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Preclinical data to be presented highlights the potential ability to generate mbIL-15 TCR-T cells targeting hotspot mutations expressed in solid tumors with enhanced survival capacity.
Lead Product(s): mbIL-15 TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
First-in-human non-viral TCR-T cell therapy, of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.
Lead Product(s): TCR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Interim data from the phase 2 study of Controlled IL-12 and cemiplimab combo to treat rGBM, updated interim data from the phase 1 study of Controlled IL-12 and nivolumab for rGBM, and data from phase 1/2 study of Controlled IL-12 monotherapy to treat DIPG to be presented.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
FDA has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain.
Lead Product(s): Ad-RTS-hIL-12,Veledimex
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
